Hongliang Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5014278/publications.pdf

Version: 2024-02-01

181	12,557	34105	30087
papers	citations	52 h-index	103 g-index

185	185	185	18772
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism, 2020, 31, 1068-1077.e3.	16.2	1,207
2	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research, 2020, 126, 1671-1681.	4.5	948
3	The Science Underlying COVID-19. Circulation, 2020, 142, 68-78.	1.6	682
4	Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radical Biology and Medicine, 2020, 152, 116-141.	2.9	574
5	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metabolism, 2020, 32, 176-187.e4.	16.2	400
6	Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Metaâ€Analysis. Hepatology, 2019, 70, 1119-1133.	7.3	355
7	Longitudinal Association Between Markers of Liver Injury and Mortality in COVIDâ€19 in China. Hepatology, 2020, 72, 389-398.	7.3	346
8	Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology, 2020, 71, 1851-1864.	7.3	341
9	The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nature Medicine, 2016, 22, 1131-1139.	30.7	331
10	Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology, 2016, 151, 733-746.e12.	1.3	235
11	Autoimmune Basis for Postural Tachycardia Syndrome. Journal of the American Heart Association, 2014, 3, e000755.	3.7	199
12	Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nature Medicine, 2017, 23, 439-449.	30.7	183
13	Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 365-378.	3.8	176
14	An ALOX12â€“12-HETEâ€“GPR31 signaling axis is a key mediator of hepatic ischemiaâ€“reperfusion injury. Nature Medicine, 2018, 24, 73-83.	30.7	155
15	The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. Hepatology, 2019, 70, 1026-1037.	7.3	146
16	The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. Nature Medicine, 2018, 24, 84-94.	30.7	145
17	The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling. Nature Communications, 2016, 7, 11267.	12.8	143
18	Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13818-13823.	7.1	125

#	Article	IF	Citations
19	IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nature Communications, 2014, 5, 3303.	12.8	124
20	Nonalcoholic Fatty Liver Disease. Hypertension, 2020, 75, 275-284.	2.7	121
21	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circulation Research, 2020, 126, 679-704.	4.5	121
22	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism, 2020, 32, 537-547.e3.	16.2	116
23	Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. Journal of Hepatology, 2016, 64, 1365-1377.	3.7	113
24	Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E1234-E1244.	3.5	112
25	Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace, 2017, 19, 1211-1219.	1.7	110
26	Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Medicinal Research Reviews, 2019, 39, 328-348.	10.5	105
27	Perioperative Presentation of COVIDâ€19 Disease in a Liver Transplant Recipient. Hepatology, 2020, 72, 1491-1493.	7.3	102
28	Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. Nature Communications, 2016, 7, 10592.	12.8	95
29	Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 892-908.e11.	16.2	92
30	AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1844-1854.	3.8	91
31	Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. Journal of Nutritional Biochemistry, 2010, 21, 1238-1250.	4.2	89
32	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metabolism, 2021, 33, 258-269.e3.	16.2	87
33	Activation of integrin Î±5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 769-774.	7.1	85
34	Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease. Trends in Endocrinology and Metabolism, 2019, 30, 903-914.	7.1	85
35	Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury. Journal of Hepatology, 2016, 64, 146-159.	3.7	79
36	Response by Zhang et al to Letter Regarding Article, â€œAssociation of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19â€• Circulation Research, 2020, 126, e142-e143.	4.5	79

#	Article	IF	Citations
37	Interferon Regulatory Factor 1 Is Required for Cardiac Remodeling in Response to Pressure Overload. Hypertension, 2014, 64, 77-86.	2.7	75
38	Puerarin attenuates pressure overload-induced cardiac hypertrophy. Journal of Cardiology, 2014, 63, 73-81.	1.9	73
39	Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-Î±/ASK1/JNK pathway. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1143-H1154.	3.2	71
40	The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis. Hepatology, 2017, 65, 1492-1511.	7.3	70
41	Angiotensin II Type 1 Receptor Autoantibodies in Postural Tachycardia Syndrome. Journal of the American Heart Association, 2018, 7, .	3.7	67
42	Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. Trends in Endocrinology and Metabolism, 2018, 29, 712-722.	7.1	66
43	Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 153-184.	22.4	65
44	Long non-coding RNA PVT1-5 promotes cell proliferation by regulating miR-126/SLC7A5 axis in lung cancer. Biochemical and Biophysical Research Communications, 2018, 495, 2350-2355.	2.1	64
45	Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E197-E209.	3.5	63
46	Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. Journal of Hepatology, 2015, 62, 111-120.	3.7	62
47	Interferon regulatory factor 9 is critical for neointima formation following vascular injury. Nature Communications, 2014, 5, 5160.	12.8	61
48	Suppressor of IKKÉ› is an essential negative regulator of pathological cardiac hypertrophy. Nature Communications, 2016, 7, 11432.	12.8	60
49	TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. Cell Metabolism, 2020, 31, 726-740.e8.	16.2	60
50	Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metabolism, 2021, 33, 1943-1956.e2.	16.2	59
51	AMPK Suppresses Vascular Inflammation In Vivo by Inhibiting Signal Transducer and Activator of Transcription-1. Diabetes, 2015, 64, 4285-4297.	0.6	58
52	A Critical Role for Interferon Regulatory Factor 9 in Cerebral Ischemic Stroke. Journal of Neuroscience, 2014, 34, 11897-11912.	3.6	57
53	Innate immune regulatory networks in hepatic lipid metabolism. Journal of Molecular Medicine, 2019, 97, 593-604.	3.9	57
54	Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. Physiological Reviews, 2019, 99, 893-948.	28.8	57

#	Article	IF	Citations
55	ACE2 the Janus-faced protein â€“ from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clinical Science, 2020, 134, 747-750.	4.3	57
56	DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. Journal of Hepatology, 2016, 65, 113-124.	3.7	55
57	Hepatocyte TNF Receptorâ€“Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6â€“Linked Polyubiquitination of Apoptosis Signalâ€Regulating Kinase 1. Hepatology, 2020, 71, 93-111.	7.3	55
58	Oncostatin M receptor Î² deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. Journal of Lipid Research, 2017, 58, 895-906.	4.2	53
59	Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 412-414.	3.0	51
60	Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor Î± in mice. Journal of Hepatology, 2014, 60, 1046-1054.	3.7	50
61	Dusp14 protects against hepatic ischaemiaâ€“reperfusion injury via Tak1 suppression. Journal of Hepatology, 2018, 68, 118-129.	3.7	50
62	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circulation Research, 2021, 128, 1747-1765.	4.5	49
63	Agonistic Autoantibodies as Vasodilators in Orthostatic Hypotension. Hypertension, 2012, 59, 402-408.	2.7	48
64	Tumor Necrosis Factor Receptorâ€“Associated Factor 3 Is a Positive Regulator of Pathological Cardiac Hypertrophy. Hypertension, 2015, 66, 356-367.	2.7	48
65	Mindin regulates vascular smooth muscle cell phenotype and prevents neointima formation. Clinical Science, 2015, 129, 129-145.	4.3	47
66	Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med, 2021, 2, 38-48.e2.	4.4	47
67	Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an â€œautoimmuneâ€• orthostatic hypotension. Journal of the American Society of Hypertension, 2012, 6, 40-47.	2.3	46
68	Insights into innate immune signalling in controlling cardiac remodelling. Cardiovascular Research, 2017, 113, 1538-1550.	3.8	46
69	Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1. Journal of Hepatology, 2018, 69, 1110-1122.	3.7	46
70	Integrated Omics Reveals Tollip as an Regulator and Therapeutic Target for Hepatic Ischemiaâ€Reperfusion Injury in Mice. Hepatology, 2019, 70, 1750-1769.	7.3	44
71	Fatty Acid Synthaseâ€“Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD. Hepatology, 2021, 74, 2508-2525.	7.3	44
72	Interferon Regulatory Factor Signalings in Cardiometabolic Diseases. Hypertension, 2015, 66, 222-247.	2.7	43

#	Article	IF	Citations
73	Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor Î²â€“Activated Kinase 1â€“Dependent Signaling Pathways. Hypertension, 2017, 69, 249-258.	2.7	43
74	Regulator of G-Protein Signaling 10 Negatively Regulates Cardiac Remodeling by Blocking Mitogen-Activated Protein Kinaseâ€“Extracellular Signal-Regulated Protein Kinase 1/2 Signaling. Hypertension, 2016, 67, 86-98.	2.7	42
75	Ca ²⁺ -Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species Production. Hypertension, 2020, 76, 827-838.	2.7	42
76	Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. Journal of Hepatology, 2016, 65, 125-136.	3.7	41
77	Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Betaâ€“Activated Kinase 1â€“câ€Junâ€Nâ€Terminal Kinase/p38 Signaling. Hepatology, 2021, 73, 104-125.	7.3	40
78	Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway. Hypertension, 2017, 70, 770-779.	2.7	37
79	Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferatorâ€Activated Receptor Î³ in Mice. Hepatology, 2019, 69, 2471-2488.	7.3	37
80	Fâ€box/WD Repeatâ€Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signalâ€Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice. Hepatology, 2019, 70, 1942-1957.	7.3	36
81	Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. Cell Metabolism, 2021, 33, 2059-2075.e10.	16.2	35
82	Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications. Hepatology, 2021, 74, 2839-2847.	7.3	35
83	The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases. British Journal of Pharmacology, 2015, 172, 5457-5476.	5.4	34
84	Mindin deficiency protects the liver against ischemia/reperfusion injury. Journal of Hepatology, 2015, 63, 1198-1211.	3.7	34
85	Oncostatin M Confers Neuroprotection against Ischemic Stroke. Journal of Neuroscience, 2015, 35, 12047-12062.	3.6	34
86	Regulator of <scp>G</scp>â€protein signalling 5 protects against atherosclerosis in apolipoprotein <scp>E</scp>â€deficient mice. British Journal of Pharmacology, 2015, 172, 5676-5689.	5.4	34
87	Neuron-Specific Tumor Necrosis Factor Receptorâ€“Associated Factor 3 Is a Central Regulator of Neuronal Death in Acute Ischemic Stroke. Hypertension, 2015, 66, 604-616.	2.7	33
88	Interferon Regulatory Factor 4 Inhibits Neointima Formation by Engaging KrÃ¼ppel-Like Factor 4 Signaling. Circulation, 2017, 136, 1412-1433.	1.6	33
89	Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: a systematic analysis of GBD 2019 data. Respiratory Research, 2022, 23, 90.	3.6	33
90	Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy. Circulation, 2018, 137, 1486-1504.	1.6	32

#	Article	IF	Citations
91	Caspase Recruitment Domain 6 Protects Against Cardiac Hypertrophy in Response to Pressure Overload. Hypertension, 2014, 64, 94-102.	2.7	30
92	Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy. Hypertension, 2015, 65, 871-881.	2.7	30
93	Hepatic Oncostatin M Receptor Î² Regulates Obesity-Induced Steatosis and Insulin Resistance. American Journal of Pathology, 2016, 186, 1278-1292.	3.8	30
94	Mnk1 (Mitogen-Activated Protein Kinaseâ€“Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice. Hypertension, 2016, 68, 1393-1399.	2.7	30
95	Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. Journal of Infection and Public Health, 2022, 15, 13-20.	4.1	30
96	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. Science Translational Medicine, 2021, 13, eabg8116.	12.4	30
97	Time to stepâ€up the fight against NAFLD. Hepatology, 2018, 67, 2068-2071.	7.3	29
98	Dickkopfâ€3 Ablation Attenuates the Development of Atherosclerosis in ApoEâ€Deficient Mice. Journal of the American Heart Association, 2017, 6, .	3.7	28
99	Interferon Regulatory Factor 7 Protects Against Vascular Smooth Muscle Cell Proliferation and Neointima Formation. Journal of the American Heart Association, 2014, 3, e001309.	3.7	27
100	Milk Fat Globuleâ€“Epidermal Growth Factorâ€“Factor 8 Improves Hepatic Steatosis and Inflammation. Hepatology, 2021, 73, 586-605.	7.3	27
101	Cellular FLICE-Inhibitory Protein Protects Against Cardiac Remodeling Induced by Angiotensin II in Mice. Hypertension, 2010, 56, 1109-1117.	2.7	26
102	Tollip is a critical mediator of cerebral ischaemiaâ€“reperfusion injury. Journal of Pathology, 2015, 237, 249-262.	4.5	25
103	Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells. Cancer Management and Research, 2018, Volume 10, 6599-6609.	1.9	25
104	A Maitake (Grifola frondosa) polysaccharide ameliorates Alzheimer's disease-like pathology and cognitive impairments by enhancing microglial amyloid-Î² clearance. RSC Advances, 2019, 9, 37127-37135.	3.6	25
105	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clinical Science, 2020, 134, 1775-1799.	4.3	25
106	Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Frontiers in Medicine, 2021, 8, 761538.	2.6	25
107	Exacerbating Pressure Overloadâ€“Induced Cardiac Hypertrophy. Hypertension, 2015, 66, 571-581.	2.7	24
108	Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Hypertension, 2017, 69, 510-520.	2.7	24

#	Article	IF	Citations
109	Reprogramming Interferon Regulatory Factor Signaling in Cardiometabolic Diseases. Physiology, 2017, 32, 210-223.	3.1	24
110	Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. International Journal of Neuropsychopharmacology, 2015, 18, pyv021-pyv021.	2.1	23
111	Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction. Basic Research in Cardiology, 2015, 110, 56.	5.9	23
112	Reprogramming Innate Immune Signaling in Cardiometabolic Disease. Hypertension, 2017, 69, 747-760.	2.7	23
113	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expression, 2019, 19, 187-198.	1.2	23
114	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. Science Translational Medicine, 2021, 13, eabg8117.	12.4	23
115	TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. Cell Metabolism, 2021, 33, 1640-1654.e8.	16.2	22
116	Pivotal Role of Regulator of G-protein Signaling 12 in Pathological Cardiac Hypertrophy. Hypertension, 2016, 67, 1228-1236.	2.7	21
117	The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy. Circulation Research, 2022, 130, 1586-1600.	4.5	21
118	Atrial tachycardia provoked in the presence of activating autoantibodies to Î²2-adrenergic receptor in the rabbit. Heart Rhythm, 2013, 10, 436-441.	0.7	20
119	Interferon regulatory factor 3 protects against adverse neo-intima formation. Cardiovascular Research, 2014, 102, 469-479.	3.8	20
120	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expression, 2019, 19, 175-185.	1.2	20
121	TNFAIP3 Interacting Protein 3 Is an Activator of Hippoâ€YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury. Hepatology, 2021, 74, 2133-2153.	7.3	20
122	High Remnant Cholesterol Level Potentiates the Development of Hypertension. Frontiers in Endocrinology, 2022, 13, 830347.	3.5	20
123	Inducible cardiac arrhythmias caused by enhanced Î²₁-adrenergic autoantibody expression in the rabbit. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H422-H428.	3.2	19
124	Calponin1 inhibits dilated cardiomyopathy development in mice through the ÎµPKC pathway. International Journal of Cardiology, 2014, 173, 146-153.	1.7	19
125	Tollâ€interacting protein contributes to mortality following myocardial infarction through promoting inflammation and apoptosis. British Journal of Pharmacology, 2015, 172, 3383-3396.	5.4	19
126	Activating autoantibodies to the Î²1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism. Endocrine, 2015, 49, 457-463.	2.3	18

#	Article	IF	Citations
127	Nâ€acetylgalactosaminyltransferaseâ€4 protects against hepatic ischemia/reperfusion injury by blocking apoptosis signalâ€regulating kinase 1 Nâ€terminal dimerization. Hepatology, 2022, 75, 1446-1460.	7.3	18
128	The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes?. Cancer Letters, 2017, 387, 46-60.	7.2	17
129	NAFLD as a continuous driver in the whole spectrum of vascular disease. Journal of Molecular and Cellular Cardiology, 2022, 163, 118-132.	1.9	17
130	Attenuation of cerebral ischemic injury in interferon regulatory factor 3â€deficient rat. Journal of Neurochemistry, 2016, 136, 871-883.	3.9	16
131	Cardiac-Specific EPI64C Blunts Pressure Overloadâ€“Induced Cardiac Hypertrophy. Hypertension, 2016, 67, 866-877.	2.7	16
132	Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (Interferon) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	2.7	16
133	Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges. Current Drug Targets, 2017, 18, 1754-1778.	2.1	16
134	Projection of global burden and risk factors for aortic aneurysm â€“ timely warning for greater emphasis on managing blood pressure. Annals of Medicine, 2022, 54, 553-564.	3.8	16
135	A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis. Hepatology, 2022, 75, 403-418.	7.3	15
136	Cardioprotective role of growth/differentiation factor 1 in postâ€infarction left ventricular remodelling and dysfunction. Journal of Pathology, 2015, 236, 360-372.	4.5	14
137	Type III Transforming Growth Factor-Î² Receptor Drives Cardiac Hypertrophy Through Î²-Arrestin2â€“Dependent Activation of Calmodulin-Dependent Protein Kinase II. Hypertension, 2016, 68, 654-666.	2.7	14
138	Never in Mitosis Gene A Related Kinase-6 Attenuates Pressure Overload-Induced Activation of the Protein Kinase B Pathway and Cardiac Hypertrophy. PLoS ONE, 2014, 9, e96095.	2.5	14
139	Heavy Disease Burden of High Systolic Blood Pressure During 1990-2019: Highlighting Regional, Sex, and Age Specific Strategies in Blood Pressure Control. Frontiers in Cardiovascular Medicine, 2021, 8, 754778.	2.4	14
140	Î²1-Adrenergic and M2 Muscarinic Autoantibodies and Thyroid Hormone Facilitate Induction of Atrial Fibrillation in Male Rabbits. Endocrinology, 2016, 157, 16-22.	2.8	13
141	Vinexin Î² Ablation Inhibits Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice by Inactivating the Aktâ€“Nuclear Factor ÎºB Inflammatory Axis. Journal of the American Heart Association, 2017, 6, .	3.7	13
142	A peptidomimetic inhibitor suppresses the inducibility of Î²1-adrenergic autoantibody-mediated cardiac arrhythmias in the rabbit. Journal of Interventional Cardiac Electrophysiology, 2015, 44, 205-212.	1.3	12
143	Liver capsule: IRFs in hepatocytes: Pathophysiology. Hepatology, 2016, 63, 1706-1706.	7.3	12
144	Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy. Drug Metabolism and Pharmacokinetics, 2019, 34, 165-171.	2.2	12

#	Article	IF	Citations
145	A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. Frontiers in Endocrinology, 2022, 13, 821689.	3.5	12
146	Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-ÎºB pathway. Journal of Molecular Medicine, 2020, 98, 691-705.	3.9	11
147	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. Current Medical Research and Opinion, 2021, 37, 917-927.	1.9	11
148	Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD. Hepatology, 2021, 74, 1319-1338.	7.3	11
149	Atrial Tachyarrhythmias Induced by the Combined Effects of Î²1/2-adrenergic Autoantibodies and Thyroid Hormone in the Rabbit. Journal of Cardiovascular Translational Research, 2014, 7, 581-589.	2.4	10
150	Tollip Negatively Regulates Vascular Smooth Muscle Cellâ€“Mediated Neointima Formation by Suppressing Aktâ€Ðependent Signaling. Journal of the American Heart Association, 2018, 7, .	3.7	10
151	The Role of GnRH Receptor Autoantibodies in Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2020, 4, bvaa078.	0.2	10
152	A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. Cell Metabolism, 2021, 33, 1171-1186.e9.	16.2	10
153	Therapeutic Potential of G Proteinâ€Coupled Receptors Against Nonalcoholic Steatohepatitis. Hepatology, 2021, 74, 2831-2838.	7.3	10
154	Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. American Journal of Physiology - Cell Physiology, 2022, 323, C630-C639.	4.6	10
155	Targeting ACC for NASH resolution. Trends in Molecular Medicine, 2022, 28, 5-7.	6.7	9
156	Vinexin-Î² exacerbates cardiac dysfunction post-myocardial infarction via mediating apoptotic and inflammatory responses. Clinical Science, 2015, 128, 923-936.	4.3	8
157	Activation of Î±7nAChR via vagus nerve prevents obesity-induced insulin resistance via suppressing endoplasmic reticulum stress-induced inflammation in Kupffer cells. Medical Hypotheses, 2020, 140, 109671.	1.5	8
158	Melanoma differentiationâ€”Associated gene 5 protects against NASH in mice. Hepatology, 2022, 75, 924-938.	7.3	8
159	Loss of Caspaseâ€Activated DNase Protects Against Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Journal of the American Heart Association, 2016, 5, .	3.7	7
160	A functional cell-based bioassay for assessing adrenergic autoantibody activity in postural tachycardia syndrome. Journal of Translational Autoimmunity, 2019, 2, 100006.	4.0	7
161	A Polysaccharide Extract from Maitake Culinary-Medicinal Mushroom, Grifola frondosa (Agaricomycetes) Ameliorates Learning and Memory Function in Aluminum Chloride-Induced Amnesia in Mice. International Journal of Medicinal Mushrooms, 2019, 21, 1065-1074.	1.5	7
162	Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy. Bioscience Reports, 2020, 40, .	2.4	7

#	Article	IF	Citations
163	Transcutaneous vagus nerve stimulation attenuates autoantibody-mediated cardiovagal dysfunction and inflammation in a rabbit model of postural tachycardia syndrome. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 291-300.	1.3	7
164	Global death burden and attributable risk factors of peripheral artery disease by age, sex, SDI regions, and countries from 1990 to 2030: Results from the Global Burden of Disease study 2019. Atherosclerosis, 2022, 347, 17-27.	0.8	7
165	Vinexinâ€Î² deficiency protects against cerebral ischaemia/reperfusion injury by inhibiting neuronal apoptosis. Journal of Neurochemistry, 2015, 134, 211-221.	3.9	6
166	Ganglionated Plexi Ablation Suppresses Chronic Obstructive Sleep Apnea-Related Atrial Fibrillation by Inhibiting Cardiac Autonomic Hyperactivation. Frontiers in Physiology, 2021, 12, 640295.	2.8	6
167	Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome. Journal of Cardiovascular Translational Research, 2022, 15, 438-440.	2.4	6
168	High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer. PeerJ, 2020, 8, e10397.	2.0	6
169	Gonadotrophinâ€releasing hormone receptor autoantibodies induce polycystic ovary syndromeâ€like features in a rat model. Experimental Physiology, 2021, 106, 902-912.	2.0	5
170	Increased testosterone and proinflammatory cytokines in patients with polycystic ovary syndrome correlate with elevated GnRH receptor autoantibody activity assessed by a fluorescence resonance energy transfer-based bioassay. Endocrine, 2021, 74, 163-171.	2.3	5
171	Cisapride, a selective serotonin 5-HT4-receptor agonist, inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. Biochemical and Biophysical Research Communications, 2016, 478, 1423-1428.	2.1	4
172	Wang et al. reply. Nature Medicine, 2018, 24, 700-701.	30.7	3
173	M 2 muscarinic autoantibodies and thyroid hormone promote susceptibility to atrial fibrillation and sinus tachycardia in an autoimmune rabbit model. Experimental Physiology, 2021, 106, 882-890.	2.0	3
174	Griflola frondosa (GF) produces significant antidepressant effects involving AMPA receptor activation in mice. Pharmaceutical Biology, 2017, 55, 299-305.	2.9	2
175	Autoimmune activation of the GnRH receptor induces insulin resistance independent of obesity in a female rat model. Physiological Reports, 2021, 8, e14672.	1.7	2
176	GnRH receptor-activating autoantibodies in polycystic ovary syndrome: identification of functional epitopes and development of epitope mimetic inhibitors. Endocrine, 2021, , 1.	2.3	2
177	Reply to: â€œInterferon regulatory factor 9 plays a dual function in health and diseaseâ€. Journal of Hepatology, 2015, 62, 1447-1448.	3.7	1
178	A novel RIT1 mutation causes deterioration of Noonan syndrome-associated cardiac hypertrophy. EBioMedicine, 2019, 42, 6-7.	6.1	1
179	SUN-LB5 GnRHR ECL-2 Epitopes Targeted by Activating Autoantibodies in Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2020, 4, .	0.2	1
180	MON-002 The Effect of GNRHR Autoantibody on Reproduction Function and Insulin Signaling Intermediates in a New Animal Model of Polycystic Ovary Syndrome. Journal of the Endocrine Society, 2020, 4, .	0.2	1

#	Article	IF	Citations
181	Reply:. Hepatology, 2019, 70, 2239-2240.	7.3	0